Continuing advances in cell and gene therapy (CGT) are transforming how biopharma companies treat and potentially cure certain diseases. Browse our collection of articles for an in-depth look at the opportunities, challenges, and implications for stakeho
故仅计算全身 性给药基因疗法对于病毒载体的需求。 根据Cell and Gene Therapy Insights 对 AAV 生产参数的假设,生产一剂 (1.3*1015 vg)AAV 所需成本(包括培养基、层析介质、质粒、QAQC、人 工等)约为 10.4 万美元, 我们假设毛利约为 55%(参考 Oxford Biomedica 财报),则一剂 AAV 报价约为 23 万美元; Ev...
Our cell and gene therapy expertise covers a wide range of modalities, including autologous and allogeneic T-cell therapies (CAR-T, TCR, Treg), NK cells, Viral Vectors (LVV, AAV, Adeno, Oncolytic) iPSCs, HSCs, MSCs, Exosome (Extracellular vesicle)-based therapies, Dendritic cells and more...
Advanced therapy medicinal products (ATMPs) have the potential to transform medicine, with the promise to treat, manage and cure some of the most severe diseases. However, the development of ATMPs is complex and successful transition from preclinical research to the approved clinical product faces a...
Medpace, afull-service clinical research organization(CRO), has conducted over 130 advanced therapy trials, and applies this experience to help Sponsors advance their CGT therapies. Leverage Medpace’s cross-functional cell and gene therapy clinical development services from preclinical to post-approval....
Go straight to smart. Get theDeloitte Insights app Globally, cell and gene therapies (CGT) are transforming not just how humans treat genetic and intractable diseases but are altering the entire pharmaceutical ecosystem. More than 27 CGT products were launched worldwide by end of 20...
2024 Cell and Gene Therapy Summit Explore key takeaways and expert insights to inform your CGT program Our commitment to being a concept to cure partner for advanced therapy developers continues with the second annual Cell and Gene Therapy Summit, which took place on March 19, 2024, in San Fr...
Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside Recombinant adeno-associated viruses (rAAVs) have emerged as an attractive tool for gene delivery, and demonstrated tremendous promise in gene therapy and gene editing—therapeutic modalities with potent...
Cell and Gene Therapy Global Market Report 2024 - Gene therapy involves delivering genetic material, typically through a carrier or vector, with the gene being taken up by the appropriate body cells. Cell therapy, on the other hand, entails introducing c
and case studies for cell and gene therapy R&D. They’ll both discuss the value of using a centralized software solution to help teams establish traceability throughout the R&D process, work in close collaboration, and generate meaningful insights faster. You’ll see a demonstration of solution ...